Thalys(SH:603716) Zheng Quan Ri Bao·2025-12-12 04:39Group 1 - The core point of the announcement is that Shanghai Anze Private Fund Management Co., Ltd. plans to reduce its shareholding in Saily Medical Technology Group Co., Ltd. by up to 4,202,784 shares, which represents 2% of the company's total share capital, due to its investment planning arrangements [2][10]. - The reduction will occur over a three-month period from October 30, 2025, to January 29, 2026, through centralized bidding and block trading methods [2][11]. - As of December 11, 2025, Shanghai Anze has already reduced its holdings by 1,591,200 shares, bringing its ownership down from 5.76% to 5% [2][14]. Group 2 - The reduction in shareholding does not trigger a mandatory tender offer and will not lead to changes in the company's controlling shareholder or actual controller [3][4]. - The company will ensure that Shanghai Anze complies with relevant regulations during the reduction period and will disclose information to investors [4][11]. - The total share capital of Saily Medical was 210,139,246 shares as of August 20, 2025, and increased to 210,183,386 shares by December 10, 2025, affecting the percentage calculations [2][15].